Hormonal
Tirzepatide (a dual GLP-1/GIP agonist) is more effective than semaglutide (1.0 mg weekly) for inducing weight loss and improving metabolic markers in patients with type 2 diabetes.
If semaglutide does not provide sufficient weight loss or metabolic control, switching to tirzepatide (5-15 mg weekly) may offer significantly greater benefits. Tirzepatide, which targets both GLP-1 and GIP receptors, has been shown to produce larger weight reductions and better improvements in blood sugar and blood pressure compared to semaglutide in patients with Type 2 Diabetes.
Conversely, all doses of tirzepatide were associated with greater reductions in weight than 1.0-mg semaglutide... Tirzepatide, however, at doses of 5, 10 and 15 mg appeared superior in FPG reduction than 1.0-mg semaglutide
Why this rating
Based on direct comparisons in included RCTs (specifically Pratley et al.).
Source
Weight loss with subcutaneous semaglutide versus other glucagon‐like peptide 1 receptor agonists in type 2 diabetes: a systematic review
Brandon Stretton et al. · Internal Medicine Journal · 2023
DOI 10.1111/imj.16126
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →